Kanamycin of Lizhu pharmaceutical has passed the PQ certification of who and entered the international market
-
Last Update: 2019-02-15
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Today (February 15) Lizhu pharmaceutical announced that its wholly-owned subsidiary Lizhu group Lizhu pharmaceutical factory has received the PQ (pre certification) confirmation letter issued by the World Health Organization (who), confirming that its independently developed kanamycin injection has passed the WHO PQ certification This also means that kanamycin injection has been officially listed in the WHO recommended procurement list and the international market channels have been opened It is reported that kanamycin injection combined with other antituberculous drugs is mainly used to treat various forms of tuberculosis caused by Mycobacterium tuberculosis As of the announcement date, the cumulative R & D investment of kanamycin injection is about 6.38 million yuan The announcement also showed that in 2017, the total global sales of kanamycin preparations were US $61 million 151 thousand, an increase of 38.44% compared with 2016 Among them, the total sales volume of kanamycin injection was US $3.2426 million, an increase of 24.72% over 2016 The full text is as follows:
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
